Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VI: A Machine To Speed R&D Time, Cut Costs

Executive Summary

The biopharmaceutical industry is hoping the terms set under the negotiations with the FDA for the sixth round of the Prescription Drug User Fee Act will help reduce the time and money spent on developing medicines, allowing companies to get their products into the commercial setting quicker and maximize those therapies' potential.

Advertisement

Related Content

Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?
2020 Vision For FDA's Sentinel: 'Systemic' Integration Of Surveillance Looms
FDA To Join The 'Real World' Under PDUFA VI
Roche's Guide To Success In Oncology
GSK Leads Way With Real World Data, But Others Follow
FDA Wants Better PDUFA Fees-Goals Alignment, Predictability
Spending User Fees: Biomarker Research, Drug-Device Combos?
User fees, 'Cures,' elections: FDA bracing for the crash
Are FDA pre-filing user fees in pharma's future?
Educating Califf: Eyes opened on PDUFA, patient advocates

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel